Technology
Choose a subcategory:
Please see the Company's Annual Report on Form 10-K for the year ended December 31, 2009, as well as subsequent SEC filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties ass
As previously announced, the company received a letter from The Nasdaq Stock Market LLC on September 15, 2009, indicating that the company was not in compliance with the minimum bid price of $ 1.00 per share required by Nasdaq Marketplace R
MediciNova Reports Positive Preliminary Results From a Phase Ib Clinical Trial of MN-221 in Moderate
Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements, include, but are not limited to, the risks and uncertainties inherent in clinical trials and product d
Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical tr
FDA Concludes That Bavarian Nordic Has Fulfilled All Requirements to Support the Delivery of IMVAMUN
Anders Hedegaard, President & CEO comments: " This conclusion from the FDA concerning our manufacturing process as well as the data submitted in support of IMVAMUNE ( R) to date, marks a major milestone for Bavarian Nordic, as we now comple
StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and enabling technologies for use in stem cell-based research and drug discovery.
CHARLOTTE, N.C., March 17, 2010 ( GLOBE NEWSWIRE)-- Northera Effectively Increases SBP in Patients With Neurogenic Orthostatic Hypotension- Patients Showed Mean Diurnal Increase of 8.4 mmHg SBP and Mean Nocturnal Increase of 7.8 mmHg SBP Wh
Nabi Biopharmaceuticals Initiates Second Phase III Study for NicVAX as an Aid to Smoking Cessation a
These factors include, but are not limited to, risks relating to our ability to conduct and obtain successful results from our two Phase III clinical trials for NicVAX; GSK's failure to exercise its option for and successfully commercialize
To read the entire report visit: http:// www.investorsoup. com/lp/ BLTI See what investors say about BLTI at penny stock forum InvestorSoup. com is a small-cap research and investment commentary provider.
To read the entire report visit: http:// www.stockpreacher. com/n/ ANPI See what investors are saying about ANPI at penny stock forum StockPreacher. com is a small-cap research and investment commentary provider.
" This Notice of Allowance further validates the innovative nature of Quick-Med' s proprietary NIMBUS technology platform and underscores our company's leadership in developing the first non-leaching antimicrobial available in a wound dress
BERKELEY, Calif., March 16, 2010 ( GLOBE NEWSWIRE)- XOMA Ltd. announced today that it has received a Staff Determination letter from The NASDAQ Stock Market LLC ( " NASDAQ") indicating that the company has not regained compliance with the m